Pathological and physiological hypertrophies are regulated by distinct gene programs

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 16, Issue 6, 2009, Pages 690-697

  Beisvag, Vidar ^a,b   Kemi, Ole Johan ^a,d   Arbo, Ingerid ^a   Loennechen, Jan Pål ^a,c   Wisløff, Ulrik ^a   Langaas, Mette ^b   Sandvik, Arne Kristian ^b,c   Ellingsen, Øyvind ^a,c  

^a Department of Circulation and Medical Imaging ^*

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ACETYL COENZYME A ACYLTRANSFERASE; ACYL COENZYME A OXIDASE; ACYLTRANSFERASE; DIAZEPAM BINDING INHIBITOR; ELECTRON TRANSFERRING FLAVOPROTEIN; ENOYL COENZYME A HYDRATASE; FATTY ACID AMIDASE; FATTY ACID BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LONG CHAIN FATTY ACID COENZYME A LIGASE; MITOGEN ACTIVATED PROTEIN KINASE 14; PROPIONYL COENZYME A; PROSTAGLANDIN D2 DERIVATIVE; TRIACYLGLYCEROL LIPASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOWN REGULATION; FATTY ACID METABOLISM; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HYPERTROPHY; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; TREADMILL EXERCISE;

EID: 74249121877     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32833158a2     Document Type: Article

References (44)

1. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999; 341:1276-1283.
2. Gosse P. Left ventricular hypertrophy-the problem and possible solutions. J Int Med Res 2005; 33 (Suppl 1):3A-11A.
3. Buttrick PM, Scheuer J. Physiologic, biochemical, and coronary adaptation to exercise conditioning. Cardiol Clin 1987; 5:259-270.
4. Richey PA, Brown SP. Pathological versus physiological left ventricular hypertrophy: a review. J Sports Sci 1998; 16:129-141.
5. Iemitsu M, Miyauchi T, Maeda S, Sakai S, Kobayashi T, Fujii N, et al. Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. Am J Physiol Regul Integr Comp Physiol 2001; 281:R2029-R2036.
6. Stanton LW, Garrard LJ, Damm D, Garrick BL, Lam A, Kapoun AM, et al. Altered patterns of gene expression in response to myocardial infarction. Circ Res 2000; 86:939-945.
7. Beisvag V, Lehre PK, Midelfart H, Aass H, Geiran O, Sandvik AK, et al. Aetiology-specific patterns in end-stage heart failure patients identified by functional annotation and classification of microarray data. Eur J Heart Fail 2006; 8:381-389.
8. Iemitsu M, Maeda S, Miyauchi T, Matsuda M, Tanaka H. Gene expression profiling of exercise-induced cardiac hypertrophy in rats. Acta Physiol Scand 2005; 185:259-270.
9. Strom CC, Aplin M, Ploug T, Christoffersen TE, Langfort J, Viese M, et al. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J 2005; 272:2684-2695.
10. Geenen DL, Malhotra A, Buttrick PM. Angiotensin receptor 1 blockade does not prevent physiological cardiac hypertrophy in the adult rat. J Appl Physiol 1996; 81:816-821.
11. Hainsey T, Csiszar A, Sun S, Edwards JG. Cyclosporin A does not block exercise-induced cardiac hypertrophy. Med Sci Sports Exerc 2002; 34:1249-1254.
12. Kemi OJ, Ceci M,Wisloff U, Grimaldi S, Gallo P, Smith GL, et al. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J Cell Physiol 2008; 214:316-321.
13. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, Izumo S. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 2003; 100:12355-12360.
14. Loennechen JP, Stoylen A, Beisvag V, Wisloff U, Ellingsen O. Regional expression of endothelin-1, ANP, IGF-1, and LV wall stress in the infarcted rat heart. Am J Physiol Heart Circ Physiol 2001; 280:H2902-H2910.
15. Wisloff U, Helgerud J, Kemi OJ, Ellingsen O. Intensity-controlled treadmill running in rats: VO(2 max) and cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2001; 280:H1301-H1310.
16. Hoydal MA,Wisloff U, Kemi OJ, Britton SL, Koch LG, Smith GL, Ellingsen O. Nitric oxide synthase type-1 modulates cardiomyocyte contractility and calcium handling: association with low intrinsic aerobic capacity. Eur J Cardiovasc Prev Rehabil 2007; 14:319-325.
17. Kemi OJ, Ceci M, Condorelli G, Smith GL, Wisloff U. Myocardial sarcoplasmic reticulum Ca2 + ATPase function is increased by aerobic interval training. Eur J Cardiovasc Prev Rehabil 2008; 15:145-148.
18. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:1-25.
19. Beisvag V, Junge FK, Bergum H, Jolsum L, Lydersen S, Gunther CC, et al. Gene tools-application for functional annotation and statistical hypothesis testing. BMC Bioinform 2006; 7:470.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] Method. Methods 2001; 25:402-408.
21. Loennechen JP,Wisloff U, Falck G, Ellingsen O. Cardiomyocyte contractility and calcium handling partially recover after early deterioration during postinfarction failure in rat. Acta Physiol Scand 2002; 176:17-26.
22. Loennechen JP, Wisloff U, Falck G, Ellingsen O. Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. Circulation 2002; 105:1380-1386.
23. Kemi OJ, Haram PM, Loennechen JP, Osnes JB, Skomedal T, Wisloff U, Ellingsen O. Moderate vs. high exercise intensity: differential effects on aerobic fitness, cardiomyocyte contractility, and endothelial function. Cardiovasc Res 2005; 67:161-172.
24. Wisloff U, Loennechen JP, Currie S, Smith GL, Ellingsen O. Aerobic exercise reduces cardiomyocyte hypertrophy and increases contractility, Ca2 + sensitivity and SERCA-2 in rat after myocardial infarction. Cardiovasc Res 2002; 54:162-174.
25. Kamiyama S, Suda T, Ueda R, Suzuki M, Okubo R, Kikuchi N, et al. Molecular cloning and identification of 30-phosphoadenosine 50-phosphosulfate transporter. J Biol Chem 2003; 278:25958-25963.
26. Huopaniemi L, Kolmer M, Niittymaki J, Pelto-Huikko M, Renkonen R. Inflammationinduced transcriptional regulation of Golgi transporters required for the synthesis of sulfo sLex glycan epitopes. Glycobiology 2004; 14:1285-1294.
27. Hiscott J. Another detour on the Toll road to the interferon antiviral response. Nat Struct Mol Biol 2004; 11:1028-1030.
28. Lin Y, Zhu X, McLntee FL, Xiao H, Zhang J, Fu M, Chen YE. Interferon regulatory factor-1 mediates PPARgamma-induced apoptosis in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24:257-263.
29. Raasi S, Pickart CM. Rad23 ubiquitin-associated domains (UBA) inhibit 26 S proteasome-catalyzed proteolysis by sequestering lysine 48-linked polyubiquitin chains. J Biol Chem 2003; 278:8951-8959.
30. Zhu Q, Wani G, Wani MA, Wani AA. Human homologue of yeast Rad23 protein A interacts with p300/cyclic AMP-responsive element binding (CREB)-binding protein to down-regulate transcriptional activity of p53. Cancer Res 2001; 61:64-70.
31. Kong SW, Bodyak N, Yue P, Liu Z, Brown J, Izumo S, Kang PM. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol Genomics 2005; 21:34-42.
32. Bye A, Tjonna AE, Stolen TO, Rosbjorgen RE, Wisloff U. Transcriptional changes in blood after aerobic interval training in patients with the metabolic syndrome. Eur J Cardiovasc Prev Rehabil 2009; 16:47-52.
33. Remondino A, Rosenblatt-Velin N, Montessuit C, Tardy I, Papageorgiou I, Dorsaz PA, et al. Altered expression of proteins of metabolic regulation during remodeling of the left ventricle after myocardial infarction. J Mol Cell Cardiol 2000; 32:2025-2034.
34. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005; 352:15-35.
35. Niizeki T, Takeishi Y, Arimoto T, Nozaki N, Hirono O, Watanabe T, et al. Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circ J 2008; 72:109-114.
36. Kragten JA, van Nieuwenhoven FA, van Dieijen-Visser MP, Theunissen PH, Hermens WT, Glatz JF. Distribution of myoglobin and fatty acidbinding protein in human cardiac autopsies. Clin Chem 1996; 42:337-338.
37. FitzPatrick DR, Germain-Lee E, Valle D. Isolation and characterization of rat and human cDNAs encoding a novel putative peroxisomal enoyl-CoA hydratase. Genomics 1995; 27:457-466.
38. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 2001; 104:2923-2931.
39. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996; 94:2837-2842.
40. Finck BN. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 2007; 15:269-277.
41. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 2004; 95:568-578.
42. Neyses L, Pelzer T. The biological cascade leading to cardiac hypertrophy. Eur Heart J 1995; 16 (Suppl N):8-11.
43. Ahmed MS, Oie E, Vinge LE, Yndestad A, Oystein AG, Andersson Y, et al. Connective tissue growth factor-a novel mediator of angiotensin IIstimulated cardiac fibroblast activation in heart failure in rats. J Mol Cell Cardiol 2004; 36:393-404.
44. Diffee GM, Seversen EA, Stein TD, Johnson JA. Microarray expression analysis of effects of exercise training: increase in atrial MLC-1 in rat ventricles. Am J Physiol Heart Circ Physiol 2003; 284:H830-H837.